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Abstract:  LT-R192G, a mutant of the thermolabile enterotoxin of E. coli, is a potent 
adjuvant of immunization. Immune responses are generally analyzed at the end of 
protocols including at least 2 administrations, but rarely after a prime. To investigate this 
point, we compared B and T cell responses in mice after one and two intrarectal 
immunizations with 2/6 rotavirus-like particles (2/6-VLP) and LT-R192G. After a boost, 
we found, an unexpected lower B cell expansion measured by flow cytometry, despite a 
secondary antibody response. We then analyzed CD4
+CD25
+Foxp3
+ regulatory T cells 
(Tregs) and CD4
+CD25
+Foxp3
− helper T cells after in vitro (re)stimulation of mesenteric 
lymph node cells with the antigen (2/6-VLP), the adjuvant (LT-R192G) or both. 2/6-VLP 
did not activate CD4
+CD25
+Foxp3
− nor Foxp3
+ T cells from non-immunized and   
2/6-VLP immunized mice, whereas they did activate both subsets from mice immunized 
with 2/6-VLP in the presence of adjuvant. LT-R192G dramatically decreased 
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CD4
+CD25
+Foxp3
+ T cells from non-immunized and 2/6-VLP immunized mice but not 
from mice immunized with 2/6-VLP and adjuvant. Moreover, in this case, LT-R192G 
increased Foxp3 expression on CD4
+CD25
+Foxp3
+ cells, suggesting specific Treg 
activation during the recall. Finally, when both 2/6-VLP and LT-R192G were used for 
restimulation, LT-R192G clearly suppressed both 2/6-VLP-specific CD4
+CD25
+Foxp3
− 
and Foxp3
+ T cells. All together, these results suggest that LT-R192G exerts different 
effects on CD4
+CD25
+Foxp3
+ T cells, depending on a first or a second contact. The 
unexpected immunomodulation observed during the recall should be considered in 
designing vaccination protocols.  
Keywords: LT-R192G; Foxp3; CD25; regulatory T cells; B lymphocyte; B-1a lymphocyte; 
mucosal immunization; rotavirus 
 
1. Introduction 
Because systemic immunization is not optimal to induce local immune effectors and requires 
multiple injections, mucosal immunization is an important goal of vaccine development to protect 
against pathogens that use mucosa as portals of entry. However, several factors such as antigen 
degradation in the digestive tract, compartmentalization of the responses at the mucosa of antigen 
delivery as well as mucosal tolerance make mucosal vaccination with non replicating antigens 
complex. To generate strong mucosal immune responses, mucosal adjuvants have been proposed. The 
cholera toxin, CT, and the thermolabile enterotoxin of Escherichia coli, LT, which are well known 
diarrheagenic toxins produced by V. cholerae and enterotoxinogen E. coli, respectively, are potent 
mucosal adjuvants for abrogating mucosal tolerance and inducing strong B and T cell immune 
responses against coadministered antigens. To overcome the enterotoxicity and use them as adjuvant in 
humans, non toxic mutants of the A subunit have been developed, among them, the protease site 
mutant of LT, LT-R192G. This mutant retains adjuvant properties in experimental models [1–4] and 
has been tested in clinical trials [5–7]. However, although many studies have reported about the effects 
of the whole toxins or their mutants on different innate or adaptive immune cells that could explain the 
adjuvant effect (reviewed in [1–4,8,9]), the precise mechanism of action of these adjuvants has not 
been completely elucidated. Of note, the comparison of their different effects on immune responses 
after a prime and a boost, using the same route and the same immunogen, has not been documented. 
This comparison may bring relevant cognitive information and, in addition, it may be useful to 
optimize protocols of immunization.  
To better understand early events induced after mucosal priming with a non-replicating antigen, we 
previously traced rotavirus (RV)-specific B cells by flow cytometry (FCM), after a single intranasal 
(IN) or intrarectal (IR) administration of RV virus-like particles (2/6-VLP) in mice, in the presence of 
LT-R192G [10,11]. 2/6-VLP coadministered intranasally or intrarectally with LT-R192G, in protocols 
including at least 2 immunizations, have been shown to induce strong T and B cell responses as well as 
protection against experimental infection [12,13]. With both routes, we have shown, after a prime, 
high expansion of specific B cells in different lymphoid tissues, which depend on the route of Toxins 2010, 2                                       
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immunization. A substantial proportion of these cells expressed CD5 and was considered B-1a cells. 
Unexpectedly, we found that a second IN immunization in the same conditions did not increase the 
frequency of specific B cells on day 7 following the second immunization, whereas a secondary 
systemic and mucosal antibody response was observed [11]. As LT-R192G is a potent mucosal 
adjuvant, this result was therefore difficult to explain. We hypothesized that the massive B cell 
expansion observed when the adjuvant was used for immunization was probably regulated during the 
second contact. Such modulation may be important to avoid potential deleterious autoreactivity of 
CD5
+ expressing B-1a cells, as well as T cell-mediated inflammation. Regulatory T lymphocytes 
(Tregs) are important in suppressing the activation, proliferation and differentiation of T and B cells, 
and thus control immune responses [14,15]. Classically, Tregs are divided into two major subtypes: 
natural Tregs (nTregs) and peripherally inducible Tregs (iTregs). CD4
+ nTregs develop in the thymus 
and express CD25 and the forkhead box P3 transcription factor, Foxp3 [16]. CD4
+ iTregs include 
different subtypes, among which is a subpopulation that shares the same phenotype, CD25
+Foxp3
+, 
with nTregs [17]. In mice, Foxp3 does not make it possible to distinguish between nTregs and iTregs but is 
considered a useful marker to distinguish between CD4
+ T cells with a presumed regulatory-suppressive 
function and other CD4
+ T cells [18].  
In this work, to investigate more in details the effects of LT-R192G after a prime and a boost, we 
first compared the primary and secondary specific B cell response induced by IR immunization with 
2/6-VLP in the presence or in the absence of LT-R192G. Then, we analyzed specific CD25
+CD4
+  
T cells, both Foxp3
+ and Foxp3
−, from different lymphoid tissues, in in vitro response to 2/6-VLP,  
LT-R192G or both. Quantitative analysis reflecting activation and/or proliferative responsiveness was 
performed using cell frequency, CD25 and/or Foxp3 mean fluorescence intensity of both subsets, as 
well as IL-2 production [19].  
2. Materials and Methods 
2.1. Mice 
Pathogen-free, adult, female BALB/c mice (6–8 weeks of age) were obtained from Iffa-Credo 
(L’Arbresle, France) or from our in-house facilities. Study protocols were approved by the local 
institutional animal care committee. No mouse had evidence of previous RV infection, as determined 
by serum antibody titres. 
2.2. VLP Preparation and Adjuvant 
Two different VLP, containing RV VP2 and VP6 (2/6-VLP) used for immunization or GFP-Δ92VP2 
and VP6 used for flow cytometry, were produced in the baculovirus system as described previously [20]. 
Briefly, Sf9 insect cells were coinfected with two recombinant baculoviruses expressing the protein 
VP6 of the bovine RF strain and an authentic or a modified GFP-VP2 at a multiplicity of infection 
higher than 5PFU/cell. VLP were collected 5–7 days post infection and purified by density gradient 
centrifugation in CsCl. 
LT-R192G, a LT mutant, the thermolabile enterotoxin of Escherichia coli, was used as the 
adjuvant. LT-R192G is a mutant of LT containing a single amino acid substitution that alters the site of Toxins 2010, 2                                       
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proteolytic cleavage within the region joining A1 and A2. This mutation is associated with the reduced 
ability to induce an accumulation of cAMP in cultured cells as well as reduced enterotoxicity in 
experimental animals and humans when compared to native LT [2]. 
2.3. Immunization and Sample Collection 
The mice were intrarectally immunized on day 0 with either NaCl, 10 µg LT-R192G alone, 10 µg 
2/6-VLP alone or mixed with 10 µg LT-R192G. Prior to immunization, the mice were anesthetized by 
intraperitoneal administration of a mixture of ketamine (80 mg/kg) and xylazine (16 mg/kg). An 
additional group of mice was given two doses of 10 µg 2/6-VLP with 10 µg LT-R192G, or 2/6-VLP or 
LT-R192G alone on day 0 and on day 14. The mice were killed at different time points   
post-immunization (2, 4, 7 or 14 days) and the different lymphoid tissues, rectal follicles (RF), lumbar 
lymph nodes (LLN), mesenteric lymph nodes (MLN), Peyer’s patches (PP) and spleen were removed. 
Serum and faecal samples were collected and stored at −20 °C. 
2.4. Measurement of Rotavirus-Specific Antibodies in Serum and Fecal Samples  
Antibody titres in serum and faecal samples were determined by ELISA. Microtitre plates were 
coated overnight at 4 °C with 100 ng of 2/6-VLP in 100 µL of 0.1 M carbonate/bicarbonate buffer,  
pH 9.6. The wells were blocked with PBS containing 5% non-fat dry milk for 45 min at 37 °C. Faecal 
samples were made 10% (wt/vol) by suspension in PBS, pH 7.4. Serial twofold dilutions in PBS-5% 
non-fat dry milk of serum (starting at 1/100) or faecal extracts (starting at 1/40) were added to the 
wells and incubated for 40 min at 37 °C. After three washes with PBS-0.05% Tween 20, the plates 
were incubated for 30 min at room temperature with 1/5000 dilution of biotin-labelled goat   
anti-mouse IgA, IgG or IgM (Cell Lab, Beckman Coulter). The plates were washed, and 1/4000 of 
peroxidase-labeled avidin (Cell Lab, Beckman Coulter) was added for 30 min at room temperature. 
The colour reaction was developed with TMB-Peroxidase Substrate Kit (AbCys.S.A), stopped with 
100 µL of H2SO4 0.4N and A450 was determined. A sample was considered positive if the optical 
density of the sample well was >0.1 plus the mean of the OD values of the negative control wells. 
Titres were defined by the inverse of the highest serum dilution giving a positive signal. Negative 
serum and fecal samples (titre < 100 and <40, respectively) were arbitrarily assigned titres of 50 and 
20 (half of 100 and 40), respectively, for statistical calculations [21]. 
2.5. Preparation of Cells from RF, LLN, MLN, PP and Spleen 
Single-cell suspensions were prepared by mechanical dissociation, filtered on 40-µm-pore nylon 
meshes and washed with incomplete medium (RPMI-1640 supplemented with 0.3% glucose, 100 U 
penicillin per mL, and 100 µg streptomycin per mL). The cells were counted, labelled and analyzed 
immediately by FCM or resuspended (4 × 10
6/mL) in complete medium (incomplete medium plus 
10% heat-inactived FCS, 2 mM L-glutamine, 1 mM sodium pyruvate) for in vitro restimulation. 
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2.6. In Vitro Restimulation 
Cells from either immunized or non-immunized mice (4 × 10
5 cells/well) were cultured in 96-well 
plates in the presence of different doses of 2/6-VLP, LT-R192G, 2/6-VLP and LT-R192G or RPMI 
medium only. The T-cell mitogen concanavalin A (5 µg/mL) was used as the positive control. The 
cells were incubated at 37 °C with 5% CO2 and harvested on day 2 and day 4 after restimulation for 
flow cytometry analysis, and the culture supernatants were frozen at −40 °C until IL-2 assay.  
2.7. FCM Assays 
2.7.1. Rotavirus Specific B Cell Quantification  
To detect RV-specific B cells, we used an FCM assay as previously described [10]. Cells from 
different lymphoid tissues were washed once with PBS 1% BSA 0.1% sodium azide buffer. Pellets 
containing 2 × 10
6 cells were incubated with a mixture of PE Cy-chrome-labelled anti-B220 (Clone 
RA3-6B2, Pharmingen, San Diego, CA, USA), biotinylated anti-IgD (Clone AM9.1, Pharmingen),  
PE-labelled anti-CCR9 (Clone 248918, R&D Systems, Minneapolis, MN, USA) or anti-CD5 (Clone 
53-7.3, Pharmingen) or anti-α4β7 (clone DATK32, Pharmingen) and GFP-2/6-VLP (to detect   
RV-specific B lymphocytes) for 30 min in the dark at 4 °C. The cells were washed and then labelled 
with streptavidine-RED613 (Gibco-BRL, Scotland, UK). After incubation for 30 min in the dark at  
4 °C, the cells were washed, resuspended in buffer containing PBS 1% BSA 0.1% sodium azide, and 
analysed on a flow cytometer (LSR II, Becton Dickinson, San Jose, CA, USA). Approximately   
3 × 10
5 cells were acquired. Analysis was done as described previously [10]. Small lymphocytes were 
distinguished from large lymphocytes by their light-scatter profile. Three types of B cell subsets were 
analysed: a large B220
int IgD
− subset representing extrafollicular B cells, a large B220
high IgD
− subset 
representing germinal center B cells, and a small B220
high IgD
− subset consisting of memory and 
germinal center B cells [10]. To delineate RV-specific cell populations and to control for the 
specificity of the staining, the cells were stained, omitting GFP-VLP, and the quadrant position was 
fitted eventually, after comparison with identical B cell subsets from non-immunized mice. Absolute 
numbers of RV-specific B cells were obtained by the quantification of RV-specific B cells among total 
cells that expressed B220 (B220
high plus B220
low). In order to compare samples, the number of   
RV-specific B cells was referred to 10
5 total B220
+ cells [11]. 
2.7.2. Analysis of CD4
+CD25
+Foxp3
+ T Cells and CD4
+CD25
+Foxp3
− T Cells  
CD4
+CD25
+Foxp3
+ T cells and CD4
+CD25
+Foxp3
− T cells  were quantified  using the Mouse 
Regulatory T cell Staining kit #2 (w/APC Foxp3 FJK-16s, FITC CD4, PE CD25; eBioscience, San 
Diego, USA). Briefly, pellets containing 4x10
5 cells in 100 µL PBS 1% BSA 0.1% sodium azide, were 
incubated with a mixture of FITC-labelled anti-CD4 and PE-labelled anti-CD25 for 30 min in the dark 
at 4 °C. The cells were washed and resuspended in 1 mL of freshly prepared fixation/permeabilization 
working solution and then incubated at 4 °C for 30 min in the dark. The cells were washed with 
permeabilization buffer and then labelled with APC-labelled anti-Foxp3 for 30 min in the dark. After 
incubation, the cells were washed, resuspended in buffer containing PBS 1% BSA 0.1% sodium azide, Toxins 2010, 2                                       
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and analysed by flow cytometry. Approximately 5 × 10
4 cells were acquired. Lymphocytes were first 
identified by their light-scatter profile, and T cell subsets were then identified by CD4 expression. 
CD25
+Foxp3
+ and CD25
+Foxp3
− T cells were identified by binding of CD25 and Foxp3 within CD4
+  
T cells. The mean fluorescence intensity (MFI) for PE and APC were analyzed to detect variations in 
CD25 and Foxp3 expression, respectively.  
2.8. IL-2 Assay 
The IL-2 level in culture supernatants was determined by ELISA, using the AbC601MST Mouse 
IL-2 Module Set kit (AbCys.S.A). Briefly, microtitre plates were coated with 100 µL of anti-IL-2 
monoclonal antibody and incubated overnight at 4 °C. The wells were blocked with PBS containing 
0.5% BSA and 0.05% Tween 20 at 4 °C overnight. After two washes with PBS containing 0.05% 
Tween 20, 50 µL of supernatants were added and incubated with the biotinylated anti-IL-2 monoclonal 
antibody for 2h. The plates were washed, peroxidase-labeled streptavidine was added and the plates 
were incubated for 1h. The colour reaction was developed with TMB-Peroxidase Substrate Kit 
(AbCys.S.A), stopped with 100 µL of H2SO4 0.4 N and A450 was determined. 
2.9. Statistics 
For B cell analysis, results were expressed as means with SEM. Statistical analysis was performed 
using SigmaStat software. Pairwise comparisons between non-immunized and immunized mice were 
made using the Mann-Whitney non-parametric U-test. P-values less than 0.05 were considered 
statistically significant.  
For T cell analysis, comparison of cell frequency, CD25 and Foxp3 MFI between stimulated and non 
stimulated wells was done by using the Wilcoxon paired non-parametric signed-rank test. P-values less 
than 0.05 were considered statistically significant. In addition, comparisons between non-immunized and 
immunized mice were made using the Mann-Whitney unpaired non-parametric U-test. 
3. Results 
3.1. Primary and Secondary Specific B Cell Responses Induced by IR Immunization with 2/6-VLP with 
or without LT-R192G 
3.1.1. The Secondary Response Induced by IR Immunization with 2/6-VLP and LT-R192G Showed a 
Serum and Fecal Antibody Response but a Lower RV-Specific B Cell Expansion 
Mice were immunized once or twice with 2/6-VLP or NaCl in the presence of adjuvant, and the 
RV-specific B cell response analyzed as described previously [10]. On day 7 after the second dose, a 
secondary antibody response was observed in serum (IgA 3.7 vs. 1.7 log and IgG 5 vs. 1.7 log, for the 
secondary and primary response, respectively) and in feces (IgA 3.4 vs. 1.4 log)(Figure 1), as already 
shown with the IN route of immunization [11]. 
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Figure 3. Primary and secondary in vitro T cell responses to 2/6-VLP, LT-R192G or both 
from non-immunized mice and mice immunized with 2/6-VLP with or without   
LT-R192G. Mice were sacrificed on day 14 after one immunization and cells from MLN 
(4 × 10
5 cells/well) were cultured in the presence of Concanavalin A (5 μg/mL), antigen  
(5 μg/mL), adjuvant (5 μg/mL) or both for 2 and 4 days. Percentage of CD4
+CD25
+Foxp3
− 
and CD4
+CD25
+Foxp3
+ T cells and both CD25 and Foxp3 MFI were analyzed by flow 
cytometry and IL-2 was quantified in culture supernatants. Lymphocytes were first 
identified in a dotplot from light-scatter, and T cell subsets were then identified by 
expression of CD4. CD25
+Foxp3
+  and CD25
+Foxp3
−  T cells were then identified by 
binding of anti-CD25 and anti-Foxp3 antibodies within CD4
+ T cells. (A) Stimulation with 
Concanavalin A and quantification of IL-2 in non-immunized mice. (B)(Re) stimulation 
with antigen (5 μg/mL) in non-immunized mice and mice immunized with 2/6-VLP with 
or without LT-R192G. (C)(Re) stimulation with LT-R192G (5μg/mL) in non-immunized 
mice and mice immunized with 2/6-VLP and LT-R192G. These dotplots of one 
experiment are representative of 7 separate experiments. (D) and (E): The histograms show 
the percentage of increase or decrease for each parameter (2/6-VLP (■) or LT-R192G (■) 
or both (■)) compared to the control well (RPMI). (D) Non-immunized mice.   
(E) Immunized mice. Data represent mean ± SEM of six or seven separate experiments.  
P-values were calculated using the Wilcoxon paired non-parametric signed-rank test or the 
Mann-Whitney unpaired non-parametric U-test. * Data points statistically different 
between stimulated and RPMI wells (p = 0.01, 0.015 or 0.025). + Data points statistically 
different between 2/6-VLP and 2/6-VLP and LT-R192G stimulated wells. Percentages of 
increase or decrease compared to the control RPMI statistically different between   
non-immunized mice and immunized mice (p < 0.01 or p ≤ 0.05). nd: not determined. 
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3.2.2. Analysis of CD4
+CD25
+Foxp3
− and CD4
+CD25
+Foxp3
+ T Cells from Non-Immunized Mice 
after in Vitro Culture with 2/6-VLP or LT-R192G or Both 
In vitro culture without restimulation (RPMI medium) showed a decrease in CD4
+CD25
+Foxp3
+  
T cell frequency from day 2 to day 4 (Figure 3B and 3C) as previously reported [14]. 
In vitro culture with 2/6-VLP. As expected, in vitro culture in the presence of 2/6-VLP did not 
activate CD4
+CD25
+Foxp3
− T cells from non-immunized mice as shown by the stability of CD25 and 
the lack of IL-2 production (Figures 3B and 3D1). No increase in CD25 or in Foxp3 expression by 
CD4
+CD25
+Foxp3
+ cells was observed in the presence of 2/6-VLP (Figures 3B and 3D2). Of note, on 
day 2, there was a weak increase in CD4
+CD25
+Foxp3
− cell percentage (p = 0.01) going with a weak 
decrease of CD4
+CD25
+Foxp3
+ cell percentage. This could be explained by a decrease of Foxp3 
expression on day 2 and 4 (p = 0.01)(Figure 3D). 
In vitro culture with LT-R192G. As observed with 2/6-VLP, LT-R192G did not activate 
CD4
+CD25
+Foxp3
− nor CD4
+CD25
+Foxp3
+ T cells from non-immunized mice as shown by the lack 
of increase of CD25 and Foxp3 MFI and the lack of IL-2 production (Figures 3C and 3D). At the 
opposite and unlike 2/6-VLP, a significant decrease of CD25 expression on both CD4
+CD25
+Foxp3
−  
(p = 0.01 on day 4) and CD4
+CD25
+Foxp3
+ cells (p = 0.01 on day 2) was observed. The decrease in 
CD25 expression on CD4
+CD25
+Foxp3
+ cells was associated with a major decrease of their frequency 
from day 2 (p = 0.01). An increase in the frequency of CD4
+CD25
+Foxp3
− cells was also observed, 
notably on day 2 (p = 0.01), suggesting that a part of CD4
+CD25
+Foxp3
+ T cells did not express Foxp3 
anymore and became Foxp3
−. Of note, on day 4, CD25 and Foxp3 expression was not analyzed 
because of the very low number of remaining CD4
+CD25
+Foxp3
+ cells. 
Dose-effect. When testing different doses of LT-R192G, we observed that a dose of 0.01 µg/mL 
was sufficient to induce a decrease in CD25 expression by CD4
+CD25
+Foxp3
+ T cells (about 25%), 
suggesting the efficacy of this molecule. The maximum was observed at doses of 0.5 and 1 µg/mL 
(about 70%)(data not shown). 
In vitro culture with both 2/6-VLP and LT-R192G. When cells were cultured with both antigen and 
adjuvant, the results were similar to those observed with LT-R192G (Figure 3D). 
3.2.3 Analysis of CD4
+CD25
+Foxp3
− and CD4
+CD25
+Foxp3
+ T Cells from Mice Immunized with  
2/6-VLP Alone after in vitro Culture with 2/6-VLP or LT-R192G or Both 
The results were similar to those observed with non- immunized mice (Figure 3B, data not shown). 
3.2.4 Analysis of CD4
+CD25
+Foxp3
− and CD4
+CD25
+Foxp3
+ T Cells from Mice Immunized with  
2/6-VLP and LT-R192G and Restimulated in vitro with 2/6-VLP or LT-R192G or Both 
As for non-immunized mice and as expected, in vitro culture without restimulation (RPMI medium) 
showed a decrease in CD4
+CD25
+Foxp3
+ T cell frequency from day 2 to day 4 (Figure 3B and 3C). 
In vitro culture with 2/6-VLP. As expected, 2/6-VLP did activate CD4
+CD25
+Foxp3
− T cells as 
shown by the increase in CD25 MFI as early as day 2 (p = 0.01) and the increase in cell frequency on Toxins 2010, 2                                       
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day 4 (p = 0.01) as well as the production of IL-2 from day 2 (p = 0.005)(Figures 3B and 3E1). 
Activation of CD4
+CD25
+Foxp3
− T cells was associated with an increase in Foxp3 expression by 
CD4
+CD25
+Foxp3
+ T cells (p = 0.025 and 0.01 on day 2 and 4, respectively), followed on day 4 by an 
increase in CD25 MFI (p = 0.01) and cell frequency (p = 0.015)(Figures 3B and 3E2).  
Moreover, we have also compared the effect of the (re)stimulation between non-immunized and 
2/6-VLP and LT-R192G immunized mice and found that CD25 MFI (p < 0.01 and p < 0.05 on day 2 
and 4) for both subsets, as well as cell frequency (p < 0.01 on day 4) and Foxp3 MFI (p < 0.01 on day 
2 and 4) for CD4
+CD25
+Foxp3
+ T cells, were statistically different between non-immunized and   
2/6-VLP and LT-R192G immunized mice (Figure 3E). 
Dose-effect. We further tested different doses of 2/6-VLP and showed activation of 
CD4
+CD25
+Foxp3
− T cells (increase in CD25 expression) on day 2 from the dose of 1 µg/mL and an 
increase in their frequency on day 4 at the doses of 5 and 10 µg/mL (data not shown), which was 
consistent with IL-2 production on day 2. Activation of CD4
+CD25
+Foxp3
+ T cells (increase in CD25 
expression) was observed on day 4 from the dose of 0.5 µg/mL (data not shown). 
All together, these results suggest that CD4
+CD25
+Foxp3
+ T cells are activated when IL-2 is 
produced, i.e., when CD4
+CD25
+Foxp3
− T cells are activated [19]. This is observed only in mice 
immunized in the presence of adjuvant. 
In vitro culture with LT-R192G. Whereas IL-2 was produced (p = 0.005 on day 2 and p = 0.01 on 
day 4), no increase in CD25 MFI was observed neither by CD4
+CD25
+Foxp3
− nor by 
CD4
+CD25
+Foxp3
+ T cells (Figures 3C and 3E). At the opposite, there was a decrease in CD25 
expression on day 4 and on day 2, compared to RPMI well, for CD4
+CD25
+Foxp3
- (p = 0.025) and 
CD4
+CD25
+Foxp3
+ T cells (p = 0.015), respectively, that was not statistically different from non 
immunized mice. However, unlike control mice (p < 0.01 on day 2), CD4
+CD25
+Foxp3
+ T cells were 
activated as shown by the increase in Foxp3 expression (p = 0.01 on day 2 and p = 0.015 on day 4) 
compared to the well with RPMI medium. Foxp3 MFI was not associated with an increase in cell 
frequency, nevertheless, unlike control mice, CD4
+CD25
+Foxp3
+ T cells did not decrease compared to 
the RPMI well on day 4 (p < 0.01), and despite a transient decrease on day 2 that was clearly explained 
by the decrease of CD25 expression (the cells became CD25
−)(Figures 3C and 3E2). This result 
suggests that CD4
+CD25
+Foxp3
+ T cells were activated in response to LT-R192G and were resistant 
to LT-R192G-induced cell death unlike CD4
+CD25
+Foxp3
+ cells from non- immunized mice. 
Dose-effect. The maximum effect on CD25 expression was observed at the same doses as for 
control mice and the increase in Foxp3 expression was observed at the dose of 5 µg/mL on day 2 and 
at all the doses on day 4 (data not shown). 
All together, these results show major effects of LT-R192G on CD4
+CD25
+Foxp3
+ T cells in vitro 
which are different between non-immunized and mice immunized in the presence of adjuvant   
(i.e., first and second contact with LT-R192G). 
In vitro culture with both 2/6-VLP and LT-R192G. Compared to wells cultured in the presence of 
2/6-VLP alone, we observed a decrease in CD4
+CD25
+Foxp3
− T cell activation in the presence of  
LT-R192G as shown by the decrease in CD25 MFI, cell frequency and IL-2 production (p = 0.01 on 
day 2 and 4, p = 0.015 on day 4 and p = 0.005 on day 4, respectively)(Figure 3E1). These effects were Toxins 2010, 2                                       
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associated with a decrease in CD25 MFI and cell frequency of CD4
+CD25
+Foxp3
+ T cells (p = 0.01 on 
day 2 and day 4, for both parameters). Regarding Foxp3, it was greater on day 2 (p = 0.025) but not 
different at day 4 (Figure 3E2). 
These results show that CD4
+CD25
+Foxp3
− T cells were modulated in vitro in the presence of  
LT-R192G compared to antigen alone, which was confirmed by the fact that IL-2 production 
decreased on day 4 (Figure 3E1). 
Dose-effect. The results were confirmed using different doses of 2/6-VLP and LT-R192G in the 
same wells (5/0.1, 5/1, 5/5, 1/1 and 10/1 for the concentrations of 2/6-VLP and LT-R192G, 
respectively)(Data not shown).  
All together, our results confirm that the presence of the adjuvant substantially modulates 
CD4
+CD25
+Foxp3
+ T cells in vitro, and that the response is different in the first and second contact. 
Moreover, they show that the adjuvant controls both CD4
+CD25
+Foxp3
− and CD4
+CD25
+Foxp3
+ 
specific T cell responses induced by the antigen. 
4. Discussion 
In this work, we have shown an unexpected lower RV-specific B cell expansion measured by flow 
cytometry after two IR immunizations with RV-VLP and LT-R192G, compared to a single 
immunization, despite a trend towards a higher response on day 4 for the B220
int subset, consistent 
with a conventional secondary antibody response. Of note, the primary and secondary responses were 
not different in mice immunized in the absence of adjuvant. In these conditions, a great variability was 
observed between mice after one or two immunizations, without any correlation between the 
magnitude of the B cell response analyzed by flow cytometry and the antibody response. Analysis of 
antibody secreting cells by Elispot in the lamina propria and the bone marrow may have probably 
shown a better correlation with the antibody response. Nevertheless, these results which, confirm 
previous results obtained via the intranasal route, suggest that most B cells analyzed by FCM probably 
do not differentiate into antibody secreting cells and could have another role in the early response. 
Firstly, they may be important in antigen presentation and thus impact on T cell responses. Secondly, a 
large proportion of the B cells analyzed were B1-a cells expressing CD5, in the primary [10] as well as 
in the secondary response (data not shown). B1-a cells produce natural polyspecific antibodies which 
most likely play a role in early protection during experimental challenge. However, natural antibodies 
are also potentially auto-reactive [22], especially as high frequencies are induced. Thus, we 
hypothesized that these cells should be regulated to avoid deleterious autoreactivity. 
Immunomodulation is an intrinsic property of the immune system and is partially mediated by T cells. 
Tregs include different subsets comprising natural and inducible CD4
+ Tregs expressing CD25 and 
Foxp3 that we wanted to investigate first, notably because we hypothesized that nTregs should be 
involved early to control auto-immune reactivity. Quantitative analysis reflecting activation and/or 
proliferative responsiveness of CD4
+CD25
+Foxp3
+ T cells, presumably Tregs (nTregs or iTregs), was 
performed using cell frequency, CD25 and Foxp3 mean fluorescence intensity in in vitro culture 
experiments in the presence of the antigen, the adjuvant or both, as this method is classically used to 
study T cells [19]. This allowed us to also analyze CD4
+CD25
+Foxp3
− T cells, presumably helper  
T cells, as well as IL-2 production.  Toxins 2010, 2                                       
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In these experimental conditions, for non-immunized mice, we observed a decrease in 
CD4
+CD25
+Foxp3
+ cell frequency, from day 2 to day 4, in wells with RPMI only. This is in 
accordance with the fact that CD4
+CD25
+Foxp3
+ Tregs are dependent on IL-2 for survival [14] and no 
IL-2 was produced in these wells. However, the decrease was more important in the presence of  
LT-R192G and both 2/6-VLP and LT-R192G. Moreover, there were major differences between the 
antigen and the adjuvant, as 2/6-VLP induced a weak but homogenous decrease in Foxp3 expression 
leading to a weak decrease in CD4
+CD25
+Foxp3
+ cell frequency together with an increase in 
CD4
+CD25
+Foxp3
− cell percentage. This result suggests that 2/6-VLP could be a negative regulator of 
Foxp3 expression by nTregs, however this hypothesis has to be confirmed. Unlike 2/6-VLP,   
LT-R192G induced a major decrease of CD4
+CD25
+Foxp3
+ cells, that was only transiently associated 
with an increase in the CD4
+CD25
+Foxp3
− population. Another important difference between 2/6-VLP 
and LT-R192G was the decrease in CD25 expression induced by LT-R192G on both Foxp3
+ and 
Foxp3
− cells. This effect was observed at the dose of 0.01 µg/mL of LT-R192G with a maximum at 
the dose of 0.5–1 µg/mL, reflecting the power of this molecule. We excluded the possibility that  
LT-R192G had a toxic effect on CD4
+CD25
+Foxp3
+ cells for several reasons: firstly, LT-R192G is 
devoid of detectable in vitro ADP-ribosyltransferase activity [2]; secondly, the effect of LT-R192G on 
CD4
+CD25
+Foxp3
+ cells is different between a first contact and a recall in vitro; thirdly, no decrease 
in CD4
+CD25
+Foxp3
− T cells was observed. We suggest that LT-R192G may induce selective 
CD4
+CD25
+Foxp3
+ cell apoptosis during a first contact. Others have reported that LT induces 
apoptosis in mature lymphocytes in vitro and CD8
+ T cells were more susceptible than were CD4
+  
T cells [1]. In the same manner, CD4
+CD25
+Foxp3
+ Treg cells may be more susceptible to apoptosis 
induced by LT-R192G than CD4
+CD25
+Foxp3
− helper T cells. Thus, the effect of LT-R192G 
observed here on the CD4
+CD25
+Foxp3
+ subpopulation may be the result of selective apoptosis 
because of a higher susceptibility, compared with CD4
+Foxp3
− T cells. One hypothesis could be that 
CD4
+CD25
+Foxp3
+ cells first decrease CD25 expression before cell death by apoptosis. As 
CD4
+CD25
+Foxp3
+ cells are present at a low frequency among CD4 cells, specific labelling is 
necessary to show this effect.  
For mice immunized with 2/6-VLP and adjuvant, in vitro restimulation with the antigen showed, as 
expected, specific activation of CD4
+CD25
+Foxp3
− T cells as shown by the increase in CD25 
expression on day 2 and in cell frequency on day 4, together with IL-2 production, these effects 
increasing with the dose. The activation of CD4
+CD25
+Foxp3
− T cells was associated with the 
activation of CD4
+CD25
+Foxp3
+ T cells but with a different kinetics. Indeed, Foxp3 expression was 
first increased on day 2, followed on day 4 by CD25 expression and cell frequency, suggesting that 
activation of CD4
+CD25
+Foxp3
+ T cells is delayed, which is consistent with a feedback loop 
regulation depending on IL-2 [19]. Moreover, these activated CD4
+CD25
+Foxp3
+ T cells are probably 
2/6-VLP specific iTregs.  
Of note, T cell activation was observed for all the lymphoid organs and tissues analyzed indicating 
that T cell migration differs from B cell migration after IR immunization, as previously shown for the 
IN route. Indeed B cells were not found in PP in both cases or in the spleen with the IR route, whereas 
T cells were found in these tissues [11,23]. This result was made possible because our model allowed 
us to trace both specific B and T cells. The migration of primary and memory RV specific CD8+  
T cells in several non lymphoid and lymphoid tissues has also been reported previously [24]. To our Toxins 2010, 2                                       
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knowledge, there are no published reports of such patterns of migration showing differences between 
B and T cells after mucosal immunization. 
Unlike mice immunized with 2/6-VLP in the presence of adjuvant, no cell activation in the 
CD4
+CD25
+Foxp3
− population and no IL-2 production was observed for mice immunized with   
2/6-VLP alone. This result is in accordance with previous results [23] observed with the IN route 
which also showed a lack of IL-2 production by lymphoid cells from mice immunized with 2/6-VLP 
alone. These results suggest that the adjuvant is necessary to induce and detect a sufficient level of 
memory T cells after in vitro restimulation. No cell activation in the CD4
+CD25
+Foxp3
+ population 
was neither observed for mice immunized with 2/6-VLP alone, which is consistent with the fact that 
IL-2 is critical in CD4
+CD25
+Foxp3
+ cell activation [14] and with the model of feedback   
loop regulation. 
In vitro restimulation with LT-R192G showed important differences between mice immunized with 
2/6-VLP and adjuvant and control mice. Indeed, whereas a decrease in CD25 MFI and in 
CD4
+CD25
+Foxp3
+ cell frequency was observed on day 2 in both cases, it was associated with an 
increase in Foxp3 expression in mice immunized with 2/6-VLP and adjuvant, suggesting a specific 
recall of CD4
+CD25
+Foxp3
+ cells induced in vivo (iTregs). Moreover, on day 4, CD25 MFI as well as 
cell frequency did not decrease anymore. Similar results were observed for mice immunized with  
LT-R192G alone (data not shown). Thus the major decrease in this subpopulation, observed after a 
first contact, may be attributed to specific apoptosis of nTregs induced by LT-R192G, whereas in vivo 
induced Tregs, specific either for LT-R192G or for 2/6-VLP, may be less susceptible to apoptosis. 
Moreover, Tregs specific for LT-R192G can be recalled in vitro as shown by the increase in Foxp3 
expression and probable proliferation.  
All together, these results suggest that LT-R192G induces specific Tregs during the prime that can 
be recalled in vitro and also promotes the induction of antigen specific Tregs.  
As observed during a first contact with LT-R192G, we found a decrease in CD25 expression during 
a second contact. CD25 is the α chain of the IL-2 receptor and is necessary to form, with the β and γ 
chains, the trimeric receptor, necessary for high affinity binding of IL-2. A decrease in CD25 
expression may result in impairment in Treg maintenance and/or activation and/or function. However, 
it has been reported recently [25] that Tregs expressing a mutant IL-2Rβ chain supported suboptimal 
and transient STAT5 activation by IL-2, resulting in upregulation of Foxp3 in nTregs. This observation 
indicates that Tregs can adapt to low IL-2 through fully inducing and maintaining Foxp3 by a minimal 
requirement for IL-2 dependent STAT5 activation. Here, we observed an increase in Foxp3 expression 
in Treg cells together with a decrease in CD25 on day 2 during the recall with LT-R192G in vitro. This 
result suggests that CD4
+CD25
+Foxp3
+ cells may play a functional suppressive role despite 
impairment of IL-2 binding, which is consistent with the fact that Foxp3 expression depends in part on 
STAT5 activation.  
Finally, culture experiments in the presence of both 2/6-VLP and LT-R192G showed that   
LT-R192G clearly modulates specific CD4
+CD25
+Foxp3
− helper T cells as shown by the significant 
decrease in IL-2 production, CD25 MFI and cell frequency in wells restimulated with both 2/6-VLP 
and LT-R192G, compared to wells with 2/6-VLP alone. This was associated with a modulation of 
CD25 but not Foxp3 expression on CD4
+CD25
+Foxp3
+ T cells as well as a decrease in cell frequency. 
One may suppose that LT-R192G specific iTregs modulates the activation of CD4
+CD25
+Foxp3
−  Toxins 2010, 2                                       
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T cells, the resulting weak IL-2 production reducing the activation of 2/6-VLP specific iTregs. Of note, 
the effect of LT-R192G on CD25 expression is consistent with previous results which showed a 
decrease in CD25 expression on activated CD4
+ T cells by anti-CD3 or phytohemagglutinin [26,27], 
though in the previous experiments, CT and a mitogen or anti-CD3 were used. Moreover, we found 
that LT-R192G also modulates CD4
+ T cells, both Foxp3
+ and Foxp3
−, activated by conA   
(data not shown).  
Thus, LT-R192G which, like LT or CT, is a potent mucosal adjuvant for inducing immune B and T 
cell responses, is also able to induce specific Tregs and promote iTregs against 2/6-VLP. In 
accordance with our results, Lavelle et al. have shown that CT induces Tr1 T cells that suppressed 
IFNγ production after SC immunization [28]. We propose that Tregs induced in our model could 
modulate not only B cell expansion during the secondary response, but also memory T cell activation 
to avoid auto-immunity as well as inflammation. Of note, one cannot exclude that CD4
+CD25
+Foxp3
− 
cells contain regulatory T cells, such as Tr1 which express CD25 after activation [29].  
Induction of CD4
+CD25
+Foxp3
+ Tregs has been reported for the B subunit of CT when 
administered in a conjugated form to OVA, thus resulting in mucosal tolerance [30]. The importance 
of B cells in the induction of Tregs in this context has been reported. Moreover, it has been reported 
recently [31] that a subpopulation of B cells expressing CD1d(hi) and CD5 is a unique subset of potent 
regulatory B cells involved in auto-immunity and inflammatory models, IL-10 being a key component 
in B-cell-mediated immune regulation [32]. So, the high B cell expansion observed in our model 
during the primary response, which may have an important role in antigen presentation and in 
producing natural polyreactive antibodies, critical for protection against infection, could also play a 
role in limiting the inflammatory mechanisms and autoimmunity that could be induced in the context 
of a strong response to the presence of adjuvant. B cells may exert a regulatory role either by 
themselves and/or by inducing Tregs.  
Finally, in this work, we showed that CD4
+CD25
+Foxp3
+ T cell activation by RV 2/6-VLP was 
observed only in the context of a high immune response, when adjuvant was used for immunization. 
This is consistent with a feedback loop regulation, i.e., a specific activation of CD4
+CD25
+Foxp3
−  
T helper cells which secrete IL-2 that makes CD4
+CD25
+Foxp3
+ Tregs proliferate and in turn control 
helper T cells [19]. The impact of LT-R192G observed in vitro on cell frequency, CD25 and Foxp3 
expression suggests that this adjuvant plays an important role in modulating the CD4
+CD25
+Foxp3
+ 
Treg subpopulation. Although we could not demonstrate a direct effect of LT-R192G in vivo, we 
argue, on the basis of in vitro experiments, that the first contact in vivo with LT-R192G in a context of 
low IL-2, may induce countersuppression by decreasing Treg numbers and/or activation, thus allowing 
naïve B and T cell activation as well as B1-a cell expansion, which would account for the adjuvant 
effect. Tregs should be also induced by both the antigen and the adjuvant and may control immune 
responses during the secondary response. Specific B cells may also play a role either as regulatory  
B cells or by inducing Tregs. Consistent with our hypothesis, we found that immunization during the 
boost with 2/6-VLP alone (i.e., without adjuvant), did not induce lower Ab responses compared to a 
boost with LT-R192G (data not shown). These findings ask for the need to use the adjuvant during the 
boost, the amplitude of the memory antibody response being most likely determined during the prime.  
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5. Conclusions 
The results confirmed those obtained by the IN route for B cell responses. In addition, they showed 
an important effect of the adjuvant on CD4
+CD25
+Foxp3
+ Tregs in vitro, which was different in the 
first and second contact, as well as a negative regulation of 2/6-VLP specific CD4
+CD25
+Foxp3
+ and 
Foxp3
− T cells. These results will have to be completed by testing other antigens and adjuvants and 
should be considered for the design of mucosal vaccination protocols. 
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